Application | Comment | Organism |
---|---|---|
medicine | potential application of PRMT1 inhibitors in cancer treatment | Homo sapiens |
Inhibitors | Comment | Organism | Structure |
---|---|---|---|
4-([6-[(2H-1,3-benzodioxol-5-yl)amino]-5-nitropyrimidin-4-yl]amino)benzene-1-carboximidamide | - |
Homo sapiens | |
4-[(6-amino-5-nitropyrimidin-4-yl)amino]benzene-1-carboximidamide | - |
Homo sapiens | |
4-[(6-anilino-5-nitropyrimidin-4-yl)amino]benzene-1-carboximidamide | 0.05 mM, 9% inhibition | Homo sapiens | |
4-[[5-nitro-6-(4-sulfamoylanilino)pyrimidin-4-yl]amino]benzene-1-carboximidamide | 0.05 mM, 28% inhibition | Homo sapiens | |
4-[[6-(4-aminoanilino)-5-nitropyrimidin-4-yl]amino]benzene-1-carboximidamide | 0.05 mM, 28% inhibition | Homo sapiens | |
4-[[6-(4-carbamimidoylanilino)-5-nitropyrimidin-4-yl]amino]benzamide | - |
Homo sapiens | |
4-[[6-(4-cyanoanilino)-5-nitropyrimidin-4-yl]amino]benzene-1-carboximidamide | - |
Homo sapiens | |
4-[[6-(4-hydroxy-3,5-dimethoxyanilino)-5-nitropyrimidin-4-yl]amino]benzene-1-carboximidamide | 0.05 mM, 44% inhibition | Homo sapiens | |
N2-[6-(4-carbamimidoylanilino)-5-nitropyrimidin-4-yl]glycinamide | 0.05 mM, 49% inhibition | Homo sapiens | |
tert-butyl (4-[[6-(4-carbamimidoylanilino)-5-nitropyrimidin-4-yl]amino]phenyl)carbamate | - |
Homo sapiens |
Natural Substrates | Organism | Comment (Nat. Sub.) | Natural Products | Comment (Nat. Pro.) | Rev. | Reac. |
---|---|---|---|---|---|---|
2 S-adenosyl-L-methionine + [histone H4R3]-L-arginine | Homo sapiens | - |
2 S-adenosyl-L-homocysteine + [histone H4R3]-Nomega,Nomega-dimethyl-L-arginine | - |
? |
Organism | UniProt | Comment | Textmining |
---|---|---|---|
Homo sapiens | Q99873 | - |
- |
Substrates | Comment Substrates | Organism | Products | Comment (Products) | Rev. | Reac. |
---|---|---|---|---|---|---|
2 S-adenosyl-L-methionine + [histone H4R3]-L-arginine | - |
Homo sapiens | 2 S-adenosyl-L-homocysteine + [histone H4R3]-Nomega,Nomega-dimethyl-L-arginine | - |
? |
Synonyms | Comment | Organism |
---|---|---|
PRMT1 | - |
Homo sapiens |
protein arginine methyltransferase 1 | - |
Homo sapiens |
Ki Value [mM] | Ki Value maximum [mM] | Inhibitor | Comment | Organism | Structure |
---|---|---|---|---|---|
0.0017 | - |
4-[[6-(4-cyanoanilino)-5-nitropyrimidin-4-yl]amino]benzene-1-carboximidamide | pH and temperature not specified in the publication | Homo sapiens |
IC50 Value | IC50 Value Maximum | Comment | Organism | Inhibitor | Structure |
---|---|---|---|---|---|
0.002 | - |
pH and temperature not specified in the publication | Homo sapiens | 4-[[6-(4-cyanoanilino)-5-nitropyrimidin-4-yl]amino]benzene-1-carboximidamide | |
0.0093 | - |
pH and temperature not specified in the publication | Homo sapiens | 4-[[6-(4-carbamimidoylanilino)-5-nitropyrimidin-4-yl]amino]benzamide | |
0.013 | - |
pH and temperature not specified in the publication | Homo sapiens | tert-butyl (4-[[6-(4-carbamimidoylanilino)-5-nitropyrimidin-4-yl]amino]phenyl)carbamate | |
0.025 | - |
pH and temperature not specified in the publication | Homo sapiens | 4-([6-[(2H-1,3-benzodioxol-5-yl)amino]-5-nitropyrimidin-4-yl]amino)benzene-1-carboximidamide | |
0.038 | - |
pH and temperature not specified in the publication | Homo sapiens | 4-[(6-amino-5-nitropyrimidin-4-yl)amino]benzene-1-carboximidamide |
General Information | Comment | Organism |
---|---|---|
drug target | the enzyme (PRMT1) is a promising target for the treatment of cancer | Homo sapiens |
physiological function | overexpression or dysregulation of PRMT1 is associated with many diseases, particularly cancer | Homo sapiens |